NewsStocks

US patients struggle to obtain Eli Lilly’s half-price insulin

US patients struggle to obtain Eli Lilly’s half-price insulin (FT)

  • According to recent data from GoodRX, an app tracking drug prices, only 3% of insurance claims for Eli Lilly’s insulin were for the half-price version that the company revealed shortly before being questioned by Congress on soaring insulin prices.
  • According to the article, many pharmacists do not know that a cheaper version is available or it cannot be accessed because it wasn’t added to individual patient’s list of drugs that are covered.
  • The company said it was aggressively working to increase awareness as well as access to the cheaper diabetes drug.

Berenberg view

  • Best Healthcare analysts expect a strong downward pricing pressure and slowing volume growth for the previous classes of drugs such as DPP4 and basal insulins.
  • This will likely result in a slowdown in the sales growth for the global pharmaceutical market. We project the global diabetes pharma market to grow at only 3% CAGR to reach $46bn by 2025.
  • While the overall diabetes pharma market is set to slow, GLP1 and SGLT4 are likely to experience rapid growth.

Eli Lilly’s Share Price (USD)

Related posts

What Stock Sectors are the Smart (Big) Money Investing In?

scaredycatguide

Dave & Buster Just Got A Busted Nose

rollandthomas

How Tencent Was Impacted by China’s New Game Regulations in 2018

Mr. Crypto Lemon

Get involved!

Comments

No comments yet
Skip to toolbar